Carlyle Group Funds Fight Of Lou Gehrig’s Disease

WASHINGTON (AP) — Bloomberg LP CEO Daniel Doctoroff is joining with New York City Mayor Michael Bloomberg and David Rubenstein of Washington-based private equity firm The Carlyle Group to fund a $25 million initiative for treatment of Lou Gehrig’s disease.

They announced the three-year initiative called Target ALS on Thursday to provide a new system for sharing and coordinating findings among researchers. It will be managed by researchers at Columbia University Medical Center.

Target ALS is the next phase of a research initiative of New York-based Project A.L.S. and the Packard Center for ALS Research at Johns Hopkins University in Baltimore.

Researchers say the short-term goal is to facilitate drug-development programs at pharmaceutical and biotech companies. The longer-term goal is to find effective therapies for the disease.

(Copyright 2013 by The Associated Press. All Rights Reserved.)

blog comments powered by Disqus
Track Weather On The Go With Our App!

Listen Live